Missed Regeneron Pharmaceuticals' Rally? Here Is What Holders Saw

Radiopharmaceuticals do not usually move a biotech’s share chart on their own, yet Regeneron Pharmaceuticals’ $4.3b collaboration with Telix on solid tumor therapies gave investors a fresh, concrete bet to consider this year. Investors who held Regeneron Pharmaceuticals over the past year are up 37.6%, including dividends. If you were deciding back on 2025-11-12, what did you need to believe about these kinds of deals and the broader pipeline to feel that this outcome was plausible?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

The move put Regeneron Pharmaceuticals in the middle of this trade. Scan 35 healthcare AI stocks for other companies exposed to it.

The Two Stories Regeneron Investors Had To Weigh

The shares cost US$682 at the start of the period, so anyone looking at Regeneron Pharmaceuticals had to decide which story seemed more reasonable.

The bullish narrative pointed to a fair value of US$722, based on assumptions like 5.4% annual revenue growth and a future P/E of 16.1x, plus confidence that Dupixent and a broad pipeline would support earnings.

The bearish view put fair value at US$540 and focused on pressures. That script leaned on slow 1.4% revenue growth assumptions and the risk that healthcare reforms and biosimilars would erode margins to 22.5%.

What The Evidence Did To The Regeneron Pharmaceuticals Argument

Regeneron Pharmaceuticals’ Telix radiopharmaceutical alliance, along with new deals with Parabilis and CytomX and multiple positive trial and regulatory updates across cemdisiran, Lynozyfic, Otarmeni, Pasatru and CIDEB siRNA, leaned toward the bullish case that a broad pipeline could be important. The main caveat came from failed melanoma data and related securities lawsuits, which supported a cautious view on clinical and reputational risk.

The period highlighted how much the original thesis depended on pipeline productivity rather than headlines about “innovation.” For a different stock, track whether promised late stage programs and partnerships are reflected in revenue, absolute profit and net margin within a few years of the decision date.

What Regeneron’s One Year Run Already Prices In

Regeneron Pharmaceuticals has climbed to US$951, after investors saw a 37.6% gain over the past year. The bearish analyst Narrative on Simply Wall St still places Fair Value below that share price, even while acknowledging strong execution across Dupixent, EYLEA HD and newer siRNA and antibody programs.

The Narrative’s key concern is whether today’s valuation already assumes that pipeline assets mature smoothly into long lived profit streams. Anyone paying the current price needs to judge whether newer franchises can offset EYLEA competition, moderating Dupixent growth, higher research spend and legal risks over the next several years.

"As Regeneron Pharmaceuticals leans more heavily on its genetics, proteomics, siRNA and antibody engineering platforms to feed a roughly 50 program pipeline, there is a risk that higher ongoing research and development spending tied to these complex modalities outpaces incremental product contributions, which would weigh on operating margins and limit growth in net income even if headline revenue continues to rise."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Beyond Regeneron’s Radiopharmaceutical Story

Regeneron offers one view of complex biologic pipelines and platform bets. It is not the only approach to chronic disease exposure.

Another large drug maker is building a broad cardiometabolic and obesity franchise around incretin therapies and related combinations. It is also expanding in oncology, neuroscience, immunology and vaccines.

The shared thread is long term demand for chronic treatments, not any direct connection between these medicines. Each business is working to convert wide pipelines into durable product lines.

For your watchlist, that raises a practical question. How might a multi drug obesity and diabetes platform reshape what core pharmaceutical earnings look like?

One Narrative has already put a figure on it. → Uncover the company trading 13% below one Narrative's Fair Value

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com